Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tuvusertib by Merck for Solid Tumor: Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Tuvusertib by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
Tuvusertib by Merck for Endometrial Cancer: Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I...
Tuvusertib by Merck for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData,...
Tuvusertib by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Tuvusertib by Merck for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According to...
Tuvusertib by Merck for Epithelial Ovarian Cancer: Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase...
Tuvusertib by Merck for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tuvusertib is under clinical development by Merck and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...